Business
Sobi Q3 2025 report: Accelerated growth and portfolio momentum
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter 2025
About this update from Swedish Orphan Biovitrum Ab
[{"type":"text","content":"STOCKHOLM, Oct. 20, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter 2025","length":137,"tagName":"p"},{"type":"text","content":"Third Quarter 2025","length":18,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Total revenue increased 13 per cent, 21 per cent at constant exchange rates, (CER)1, to SEK 7,776 M (6,894)","length":107,"tagName":"p"}]},{"val":[{"type":"text","content":"Haematology revenue increased 26 per cent at CER to SEK 4,771 M (4,000), mainly driven by Altuvoct of SEK 769 M (129), strong sales of Doptelet of SEK 1,408 M (1,039) and sales of Aspaveli/Empaveli of SEK 317 M (270), somewhat offset by low Vonjo sales of SEK 307 M (379)","length":271,"tagName":"p"}]},{"val":[{"type":"text","content":"Immunology revenue increased 12 per cent at CER to SEK 2,658 M (2,583), driven by strong sales of Gamifant of SEK 733 M (405) and Kineret sales of SEK 769 M (699), somewhat offset by lower Beyfortus royalty of SEK 1,166 M (1,478)","length":229,"tagName":"p"}]},{"val":[{"type":"text","content":"Revenue from the strategic portfolio1* grew by 39 per cent at CER to SEK 5,001 M (3,830)","length":88,"tagName":"p"}]},{"val":[{"type":"text","content":"The product and marketing right Vonjo was impaired by SEK 6,612 M before tax. The impairment has not affected cash flow and is reported as items affecting comparability (IAC2)","length":175,"tagName":"p"}]},{"val":[{"type":"text","content":"The adjusted EBITA margin1,2 was 47 per cent (43), excluding IAC2 of SEK -6,664 M. EBITA1 was SEK 3,620 M (2,923), corresponding to a margin of 47 per cent (42). EBIT was SEK -3,858 M (2,038) including the impairment of Vonjo by SEK 6,612 M","length":240,"tagName":"p"}]},{"val":[{"type":"text","content":"Earnings per share (EPS) before dilution was SEK -8.40 (4.27) and EPS after dilution was SEK -8.32 (4.22). Adjusted EPS before dilution1 was SEK 6.11 (4.36) and adjusted EPS after dilution1 was SEK 6.05 (4.31). Cash flow from operating activities was SEK 1,840 M (1,201)","length":270,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":1380,"olType":false},{"type":"text","content":"Outlook 2025 - updated","length":22,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenue is anticipated to grow at low double-digit percentage at...